FDA Issues Urgent Nationwide Recall for
FDA Issues Voluntary Recall of Chantix Over Safety Concerns
The U.S. Food and Drug Administration (FDA) has announced a voluntary recall of Chantix (varenicline)
after testing found elevated levels of nitrosamines,
compounds that can increase cancer risk when present in high amounts.
The FDA said the levels detected were above its recommended safety limit,
and while the exact risk to patients remains unclear, the recall is a precautionary measure to protect public health.
“Protecting patients remains the top priority,” officials emphasized.
The recall, made in cooperation with the manufacturer,
affects certain lots of the popular stop-smoking drug,
which has helped many quit smoking.
Patients are urged not to panic but to contact their doctors about alternatives.
The FDA also urged all drugmakers to strengthen testing for nitrosamines,
noting that similar recalls have occurred with other medications in recent years.
